{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:17:07Z","timestamp":1793121427234,"version":"4.5.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","award":["14109122"],"award-info":[{"award-number":["14109122"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jhep.2025.08.018","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T23:19:18Z","timestamp":1756163958000},"page":"213-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["New targets and new drugs for hepatobiliary cancers"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-0055","authenticated-orcid":false,"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-489X","authenticated-orcid":false,"given":"Bridget P.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.08.018_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhep.2025.08.018_bib4","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2147\/JHC.S420603","article-title":"Updates in characteristics and survival rates of hepatocellular carcinoma in a nationwide cohort of real-world US patients, 2003-2021","volume":"10","author":"Tran","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.jhep.2025.08.018_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.08.018_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.08.018_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.08.018_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jhep.2025.08.018_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib14","series-title":"5,000 patients later Roche scraps its TIGIT","author":"Pileth","year":"2025"},{"key":"10.1016\/j.jhep.2025.08.018_bib15","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1016\/j.annonc.2023.09.2091","article-title":"AdvanTIG-206: phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)","volume":"34","author":"Ren","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.580","article-title":"Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma","volume":"41","author":"Acoba","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS650","article-title":"AMBER part 2F: cobolimab in combination with dostarlimab in treatment-na\u00efve patients with locally advanced\/metastatic and\/or unresectable hepatocellular carcinoma (HCC)","volume":"43","author":"Chan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021009","article-title":"Navigating the cytokine seas: targeting cytokine signaling pathways in cancer therapy","volume":"25","author":"Stanilov","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2025.08.018_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jhep.2025.08.018_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3958069","article-title":"Dual roles of IL-27 in cancer biology and immunotherapy","volume":"2017","author":"Fabbi","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jhep.2025.08.018_bib21","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/2159-8290.CD-20-1628","article-title":"IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma","volume":"12","author":"Aghayev","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.08.018_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111490","article-title":"Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27","volume":"41","author":"Skladanowska","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2025.08.018_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2501","article-title":"First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors","volume":"40","author":"Naing","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib24","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib25","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002787","article-title":"GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma","volume":"9","author":"Wang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib27","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1073\/pnas.0530278100","article-title":"Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum","volume":"100","author":"Welsh","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2025.08.018_bib28","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/gutjnl-2022-328428","article-title":"Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences","volume":"72","author":"Chen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.08.018_bib29","first-page":"218","article-title":"The expression of growth differentiation factor 15 in gallbladder carcinoma","volume":"26","author":"Yan","year":"2021","journal-title":"J BUON"},{"key":"10.1016\/j.jhep.2025.08.018_bib30","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1038\/s41586-025-08827-0","article-title":"Author Correction: neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"639","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.08.018_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2009.05382.x","article-title":"An overview of cytokines and cytokine antagonists as therapeutic agents","volume":"1182","author":"Donnelly","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jhep.2025.08.018_bib32","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.08.018_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3748\/wjg.v22.i1.275","article-title":"Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma","volume":"22","author":"Haruyama","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.08.018_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib39","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib40","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","author":"Steffin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.08.018_bib41","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2675","article-title":"ATHENA: a phase 1\/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced\/recurrent hepatocellular carcinoma (HCC)","volume":"42","author":"Hamilton","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib43","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jhep.2025.08.018_bib45","doi-asserted-by":"crossref","first-page":"12870","DOI":"10.1038\/s41598-017-12834-1","article-title":"The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma","volume":"7","author":"Bai","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.08.018_bib46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib47","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1158\/0008-5472.CAN-22-3551","article-title":"Polyunsaturated fatty acid-bound alpha-fetoprotein promotes immune suppression by altering human dendritic cell metabolism","volume":"83","author":"Munson","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41421-023-00563-x","article-title":"Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma","volume":"9","author":"He","year":"2023","journal-title":"Cell Discov"},{"key":"10.1016\/j.jhep.2025.08.018_bib49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib50","article-title":"ET140202 t-cells: a novel therapy targeting AFP\/MHC complex, that is both safe and effective in treating metastatic hepatocellular carcinoma","volume":"37","author":"Liu","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib51","series-title":"ILCA 16th annual conference; 2022 1-4 September 2022; Madrid, Spain","article-title":"Overall safety and efficacy from the phase 1 trial of ADP-A2AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma or other cancer types expressing alpha-fetoprotein","author":"Meyer","year":"2022"},{"key":"10.1016\/j.jhep.2025.08.018_bib52","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.3748\/wjg.v11.i30.4661","article-title":"Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue","volume":"11","author":"Yuan","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.08.018_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100151","article-title":"46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors","volume":"16","author":"Oh","year":"2022","journal-title":"Immuno-Oncology Technology"},{"key":"10.1016\/j.jhep.2025.08.018_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.100861","article-title":"50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies","author":"Oh","year":"2024","journal-title":"ESMO Immuno-Oncology"},{"key":"10.1016\/j.jhep.2025.08.018_bib55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12885-016-2252-y","article-title":"Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence","volume":"16","author":"Li","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib56","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1634\/stemcells.2006-0036","article-title":"The phenotypes of pluripotent human hepatic progenitors","volume":"24","author":"Schmelzer","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.jhep.2025.08.018_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhep.2025.08.018_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4034","article-title":"EpCAM CAR T (IMC001) for the treatment of advanced GI cancers","volume":"41","author":"Luo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib59","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.08.018_bib60","article-title":"Bispecific c-Met\/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jhep.2025.08.018_bib62","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","article-title":"Facts and hopes of CD40 agonists in cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1158\/2159-8290.CD-24-1215","article-title":"NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma","volume":"15","author":"Lindblad","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.08.018_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jss.2014.05.017","article-title":"Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma","volume":"192","author":"Sulpice","year":"2014","journal-title":"J Surg Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/bjc.2011.199","article-title":"Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma","volume":"105","author":"Miyamoto","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib66","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00428-011-1092-z","article-title":"Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma","volume":"459","author":"Shinozaki","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jhep.2025.08.018_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2538","article-title":"Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma","volume":"40","author":"Botta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib69","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib70","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib71","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.jhep.2025.08.018_bib72","first-page":"9","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","author":"Kirtane","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"Macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01387-8","article-title":"Targeting inflammation with chimeric antigen receptor macrophages using a signal switch","author":"Cao","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jhep.2025.08.018_bib75","article-title":"634 A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors","volume":"10","author":"Reiss","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib76","article-title":"Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma","volume":"33","author":"Suleiman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib77","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.08.018_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib79","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhep.2025.08.018_bib80","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2025.08.018_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2025.08.018_bib82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2025.08.018_bib84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2025.08.018_bib85","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/eci.12596","article-title":"The rationale for targeting TGF-beta in chronic liver diseases","volume":"46","author":"Giannelli","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jhep.2025.08.018_bib86","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib87","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib88","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib89","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2529","article-title":"Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors","volume":"42","author":"Falchook","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib90","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","article-title":"ATG-101 is a tetravalent PD-L1x4-1BB bispecific antibody that stimulates antitumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation","volume":"84","author":"Yuwen","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib91","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.08.018_bib92","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.2589","article-title":"Safety and efficacy of HB0025, an anti-PD-1\/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: preliminary results from an FIH trial","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib93","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib94","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhep.2025.08.018_bib95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2503","article-title":"A phase 1\/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: efficacy and safety results","volume":"42","author":"Segal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib96","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT111","article-title":"Abstract CT111: results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)\/CD3 bispecific antibody, in patients with advanced solid tumors","volume":"81","author":"Safran","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib97","article-title":"1074 Reversal of resistance to PD-1 checkpoint blockade in hepatocellular carcinoma by NY-303, a GPC3 NK cell engager, inhibiting Wnt-GPC3-beta catenin signaling","volume":"12","author":"Khairnar","year":"2024","journal-title":"J ImmunoTherapy Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib98","article-title":"480 A first-in-human phase I dose-escalation trial of the B7-H6\/CD3 T-cell engager BI 765049 \u00b1 ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6","volume":"9","author":"Falchook","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib99","doi-asserted-by":"crossref","first-page":"viii408","DOI":"10.1093\/annonc\/mdy288.020","article-title":"Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers","volume":"29","author":"Wermke","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-20-1328","article-title":"Conditional cancer immunotherapy as a safer way to step on the gas","volume":"11","author":"Keenan","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.08.018_bib101","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib102","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5775","article-title":"Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2\/CD3","volume":"10","author":"Slaga","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113564","article-title":"Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: current advancements and future perspectives","volume":"199","author":"ten Haaft","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib108","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib109","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2\u2013directed antibody-drug conjugate, in human epidermal growth factor receptor 2\u2013expressing or mutated advanced solid tumors: a global phase I trial","volume":"42","author":"Yao","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12094-021-02707-5","article-title":"Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance","volume":"24","author":"Murali","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-Specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.08.018_bib112","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib113","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib114","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.08.018_bib115","first-page":"17","article-title":"Why is Wnt\/beta-catenin not yet targeted in routine cancer care?","author":"de Pellegars-Malhortie","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhep.2025.08.018_bib116","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-4972","article-title":"Abstract 4972: anti-tumor activity of Helicon inhibitors of \u00df-catenin-TCF interaction in patient-derived xenograft models","volume":"83","author":"Si","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib117","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3175","article-title":"A first-in-human, phase 1\/2 trial of FOG-001, a \u03b2-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors","volume":"42","author":"Papadopoulos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib118","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.286","article-title":"Safety and biomarker assessment of ST316, a novel peptide antagonist of \u00df-catenin, in patients with advanced solid tumors","volume":"43","author":"El-Khoueiry","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib119","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhep.2025.08.018_bib121","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","article-title":"Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma","volume":"72","author":"Xiong","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.08.018_bib122","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1073\/pnas.0711281105","article-title":"PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition","volume":"105","author":"Panigrahy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2025.08.018_bib123","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41467-022-29846-9","article-title":"USP22 regulates lipidome accumulation by stabilizing PPARgamma in hepatocellular carcinoma","volume":"13","author":"Ning","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.08.018_bib124","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2767-9764.CRC-24-0082","article-title":"First-in-human phase I trial of TPST-1120, an inhibitor of PPARalpha, as monotherapy or in combination with nivolumab, in patients with advanced solid tumors","volume":"4","author":"Yarchoan","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jhep.2025.08.018_bib125","series-title":"Tempest unveils new survival data for amezalpat (TPST-1120) in randomized first-line HCC study demonstrating a six-month improvement over control arm","author":"Therapeutics","year":"2024"},{"key":"10.1016\/j.jhep.2025.08.018_bib126","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS allelic variants in biliary tract cancers","volume":"7","author":"Moffat","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2025.08.018_bib127","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrc991","article-title":"Inhibiting the p53-MDM2 interaction: an important target for cancer therapy","volume":"3","author":"Chene","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib129","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s11523-024-01086-5","article-title":"The epidemiology of biliary tract cancer and associated prevalence of MDM2 amplification: a targeted literature review","volume":"19","author":"Kratz","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.487","article-title":"Efficacy and safety of brigimadlin (BI 907828), an MDM2\u2013p53 antagonist, in patients (pts) with advanced biliary tract cancer: data from two phase Ia\/Ib dose-escalation\/expansion trials","volume":"42","author":"Macarulla","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4179","article-title":"A phase IIa\/IIb, open-label trial of BI 907828, an MDM2\u2013p53 antagonist, in patients with locally advanced\/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: brightline-2","volume":"41","author":"Goyal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib132","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2011.41.2395","volume":"30","author":"Yeo","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6804","article-title":"A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib134","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/1878-0261.12953","article-title":"Immune modulation underpins the anti-cancer activity of HDAC inhibitors","volume":"15","author":"Blaszczak","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib135","article-title":"Epigenetic remodeling of endothelial cells underlying immune checkpoint resistance in hepatocellular carcinoma","volume":"72","author":"Chen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.08.018_bib136","article-title":"Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors in hepatocellular carcinoma: a proof-of-concept clinical trial","volume":"2025","author":"Chan","year":"2025","journal-title":"The Lancet Summit: Cancer Control in China 2025"},{"key":"10.1016\/j.jhep.2025.08.018_bib137","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jhep.2021.07.029","article-title":"Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver","volume":"75","author":"Gadaleta","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib139","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.08.018_bib140","article-title":"A phase 2 study of irpagratinib (ABSK-011) plus atezolizumab in patients with advanced hepatocellular carcinoma (HCC)","volume":"35","author":"Chen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib141","doi-asserted-by":"crossref","first-page":"17","DOI":"10.17998\/jlc.20.1.17","article-title":"Histopathological variants of hepatocellular carcinomas: an update according to the 5th edition of the WHO classification of digestive system tumors","volume":"20","author":"Kim","year":"2020","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.jhep.2025.08.018_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.004","article-title":"Rare primary liver cancers: an EASL position paper","author":"Wege","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib143","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s12072-024-10694-2","article-title":"Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma","volume":"18","author":"Gong","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.08.018_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ctm2.11","article-title":"The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome","volume":"10","author":"Zheng","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jhep.2025.08.018_bib145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-21-1219","article-title":"Immune profiling of combined hepatocellular- cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.08.018_bib146","article-title":"NOTCH1 drives tumor plasticity and metastasis in hepatocellular carcinoma","author":"Lindblad","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhep.2025.08.018_bib147","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.30162","article-title":"Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma","volume":"69","author":"Liao","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.08.018_bib148","doi-asserted-by":"crossref","first-page":"393","DOI":"10.21873\/invivo.12270","article-title":"The epidemiology, staging and outcomes of sarcomatoid hepatocellular carcinoma: a SEER population analysis","volume":"35","author":"Giannis","year":"2021","journal-title":"Vivo"},{"key":"10.1016\/j.jhep.2025.08.018_bib149","doi-asserted-by":"crossref","first-page":"100042","DOI":"10.1016\/j.modpat.2022.100042","article-title":"Hepatic sarcomatoid carcinoma is an aggressive hepatic neoplasm sharing common molecular features with its conventional carcinomatous counterparts","volume":"36","author":"Yoshuantari","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2025.08.018_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1086908","article-title":"Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients","volume":"12","author":"Jia","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2025.08.018_bib151","doi-asserted-by":"crossref","first-page":"15126","DOI":"10.18632\/aging.203076","article-title":"Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma","volume":"13","author":"Luo","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jhep.2025.08.018_bib152","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/j.gastro.2014.12.028","article-title":"Unique genomic profile of fibrolamellar hepatocellular carcinoma","volume":"148","author":"Cornella","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.08.018_bib153","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2019.12.006","article-title":"BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA","volume":"72","author":"Hirsch","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.08.018_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011216","article-title":"DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma","volume":"20","author":"Ma","year":"2024","journal-title":"Plos Genet"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825024559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825024559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:16:26Z","timestamp":1766135786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825024559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0168827825024559"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.08.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets and new drugs for hepatobiliary cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}